Korea Investment Partners to finance Jlm-based Enlivex Therapeutics’s lead compound for the prevention of Graft Vs Host Disease (GVHD)

Sept 20, 2017 – Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, announced today the closing of an $8 million equity financing round at a valuation of approximately $50 Million pre-closing. Korea Investment Partners (KIP) has invested USD 6 million in the financing round, and Hadasit Bio Holdingings Ltd. (HBL) (TASE:HDST) has co-invested USD 2 million.

More on Enlivex Therapeutics Ltd.: http://www.enlivex.com/

For more information, see:- http://markets.businessinsider.com/news/stocks/Enlivex-Therapeutics-Announces-Closing-of-USD-8-Million-Series-B-Round-Led-by-KOREA-INVESTMENT-PARTNERS-KIP-and-HADASIT-BIO-HOLDINGINGS-LTD-HBL-1002384896

 

Show Buttons
Share On Facebook
Share On Twitter
Share On Google Plus
Share On Linkedin
Hide Buttons